Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

6 hrs ago | Ledger-Enquirer.com

$1,000 pill now hepatitis C treatment of choice

In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, Health Insurance, Medicaid

Mon Jul 28, 2014

SFGate

In Europe, two drugs will compete to treat rare blood cancer

In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned.

Comment?

Related Topix: Medicine, Cancer, Health, Leukemia, Biotech, Startups, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Pharmacyclics

Freshnews

Diplomat receives distribution contract for ZydeligA

Diplomat, the nation's largest independent specialty pharmacy, announced today that it has been selected as a provider of Zydelig tablets.

Comment?

Related Topix: Food and Drug Administration, Biotech, Gilead Sciences, Healthcare Industry, Leukemia, Health, Startups

TheStreet.com

Why Gilead Sciences (GILD) Stock Is Up Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Mozilla, Science / Technology, TheStreet, Financial Markets

TheStreet.com

Why Gilead Sciences (GILD) Stock Is Up Today

The company's new price target represents 41% upside from its opening price today.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Science / Technology, Financial Markets

Sat Jul 26, 2014

The Motley Fool

This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark

With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Science / Technology, Startups, CGI Pharmaceuticals, Healthcare Law, Food and Drug Administration, Law

Fri Jul 25, 2014

JD Supra

Gilead Sciences, Inc. v. Natco Pharma Ltd.

Case Name: Gilead Sciences, Inc. v. Natco Pharma Ltd. , 2013-1418, 2014 U.S. App.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Tamiflu, Oseltamivir (generic), Inventions, Science / Technology

Q-Notes

Science and Society: Let's Fight HIV and Hep C Together

Scientists and community members have striven to make their points and find common ground on this last full day of the XX International AIDS Conference on Thursday.

Comment?

Related Topix: HIV/AIDS, Health, Hepatitis, Medicine, Biotech, Gilead Sciences, Healthcare Industry, Startups, Food and Drug Administration, Prison

Investor's Business Daily

European CHMP Adopts Positive Opinion for Gilead's Zydelig ...

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorization Application for ZydeligA , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Marketing, Leukemia, Health, Lymphoma, Opinion

Medical News

$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, putting it on track to become one of the world's best-selling medicines and intensifying concerns about its costs.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Medicare, Startups

Thu Jul 24, 2014

SFGate

Gilead hepatitis C pill reaches $3.48 billion in quarterly sales

Despite criticism from insurers and lawmakers, Gilead Sciences said Wednesday its $1,000-a-day hepatitis C pill had improved on its record-setting debut as it reached $3.48 billion in sales last quarter.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Startups, CGI Pharmaceuticals, Cancer, Business News

Medical Daily

Sovaldi Debate Continues: Will Medicaid And Insurance Companies...

Since gaining approval from the Food and Drug Administration in December, Sovaldi, the hepatitis C drug, has courted controversy due to its steep $1,000-a-pill price.

Comment?

Related Topix: Hepatitis, Medicine, Medicaid, Food and Drug Administration, Biotech, Gilead Sciences, Healthcare Industry, Startups

SchaeffersResearch.com

Analyst Upgrades: Facebook Inc (FB), Delta Air Lines, Inc., and Gilead Sciences, Inc.

DAL, which has indicated it may suspend flights to the region even longer than the FAA recommends, has yet to comment on the news.

Comment?

Related Topix: Transportation, Biotech, Airlines, Medicine, Delta Air Lines, Gilead Sciences, Healthcare Industry, Startups, US News, Federal Aviation Administration, Day Trading, Financial Markets, Personal Finance

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Under this program, purchases may be ma... )--Umpqua Holdings Corporation reported net earnings available to common shareholders of $17.1 million for the second quarter of 2014.

Comment?

Related Topix: Banking, Umpqua Holdings, Financial Services, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Visa Inc., 8x8

Wed Jul 23, 2014

Customer Interaction Solutions

Gilead Announces New Agreement with Medicines Patent Pool for Access...

Gilead Sciences, Inc. announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead's investigational drug tenofovir alafenamide for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, HIV/AIDS, Health, Startups, CGI Pharmaceuticals, Australia, World News, Viread, Tenofovir (generic)

BioSpace

U.S. FDA Approves Gilead Sciences, Inc.'s Zydelig (idelalisib)...

U.S. FDA Approves Gilead Sciences, Inc. 's Zydelig For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma U.S. FDA Approves FDA's ZydeligA For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma 82 Percent Reduction in Risk of Disease Progression or Death When Combined ... (more)

Comment?

Related Topix: Biotech, Healthcare Law, Medicine, Law, Gilead Sciences, Healthcare Industry, Food and Drug Administration, Startups, CGI Pharmaceuticals, Lymphoma, Health

TheStreet.com

How Will Gilead Sciences (GILD) Stock Be Affected By Its Second Quarter Earnings Results?

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Mozilla, TheStreet, Financial Markets

Freshnews

Gilead Sciences Announces Second Quarter 2014 Financial Results

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2014.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Marketing

Pharmaceutical Processing

FDA Approves Gilead Sciences Drug for Three Cancers

The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Cancer, Health, Startups, Leukemia, Lymphoma

Seeking Alpha

Gilead Earnings Preview: Non-Sovaldi Sales Bogey May Be Unrealistic

Gilead Sciences, Inc. reports Q2 earnings tomorrow. Gilead is a biopharmaceutical company that develops and markets medicines for unmet needs.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Hepatitis, Health, Pharmaceuticals, Pharmasset

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••